Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology
作者： Larissa J. Mooney , Suzanne Nielsen , Andrew Saxon , Maureen Hillhouse , Christie Thomas
DOI: 10.1016/J.CCT.2012.11.002
关键词:
摘要: Background Effective medications to treat cocaine dependence have not been identified. Recent pharmacotherapy trials demonstrate the potential efficacy of buprenorphine (BUP) (alone or with naltrexone) for reducing use. The National Institute on Drug Abuse Clinical Trials Network (CTN) launched Cocaine Use Reduction Buprenorphine (CURB) investigation examine safety and sublingual BUP (as Suboxone®) in presence extended-release injectable naltrexone (XR-NTX, as Vivitrol®) treatment dependence. This paper describes design rationale this study.
sci-hub.se 参考文章(90)
Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. American Journal of Psychiatry. ,vol. 153, pp. 1195- 1201 ,(1996) , 10.1176/AJP.153.9.1195
Comparison of buprenorphine and methadone in the treatment of opioid dependence American Journal of Psychiatry. ,vol. 151, pp. 1025- 1030 ,(1994) , 10.1176/AJP.151.7.1025
Frank Buntinx, R Verrando, G Robaeys, Cathy Matheï, Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastro-enterologica Belgica. ,vol. 68, pp. 81- 85 ,(2005)
Linda C. Sobell, Mark B. Sobell, Timeline Follow-Back Measuring Alcohol Consumption. pp. 41- 72 ,(1992) , 10.1007/978-1-4612-0357-5_3
Barbara G Tabachnick, Linda S Fidell, Jodie B Ullman, None, Using multivariate statistics ,(1983)
Steven Shoptaw, Richard A Rawson, Michael J. McCann, Jeanne Obert, The Matrix model of outpatient stimulant abuse treatment: evidence of efficacy. Journal of Addictive Diseases. ,vol. 13, pp. 129- 141 ,(1995) , 10.1300/J069V13N04_02
François Berthou, Yvonne Dreano, Christelle Iribarne, Christian Riche, Daniel Picart, Françoise Lohezic, Dominique Carlhant, Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors Drug Metabolism and Disposition. ,vol. 26, pp. 257- 260 ,(1998)
Kabirullah Lutfy, Shoshana Eitan, Camron D. Bryant, Yu C. Yang, Nazli Saliminejad, Wendy Walwyn, Brigitte L. Kieffer, Hiroshi Takeshima, F. Ivy Carroll, Nigel T. Maidment, Christopher J. Evans, Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors The Journal of Neuroscience. ,vol. 23, pp. 10331- 10337 ,(2003) , 10.1523/JNEUROSCI.23-32-10331.2003
Susan K. McFarlin, Timothy J. O'Farrell, William Fals-Stewart, Peter Rutigliano, Timothy T. Freitas, The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. Journal of Consulting and Clinical Psychology. ,vol. 68, pp. 134- 144 ,(2000) , 10.1037//0022-006X.68.1.134
Warren K Bickel, Maxine L Stitzer, George E Bigelow, Ira A Liebson, Donald R Jasinski, Rolley E Johnson, A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts Clinical Pharmacology and Therapeutics. ,vol. 43, pp. 72- 78 ,(1988) , 10.1038/CLPT.1988.13